Magazine article Clinical Psychiatry News

Risperidone Quells Disruptive Behavior in ADHD Patients. (Adjunctive Therapy)

Magazine article Clinical Psychiatry News

Risperidone Quells Disruptive Behavior in ADHD Patients. (Adjunctive Therapy)

Article excerpt

ORLANDO, FLA. -- Risperidone is an effective adjunctive therapy to stimulants in patients with attention-deficit hyperactivity disorder and comorbid disruptive behavior disorders, Dr. Richard E. Snyder reported in a poster presentation at the American Psychiatric Association's Institute on Psychiatric Services.

Dr. Snyder, professor of pediatrics at the University of Saskatchewan, Saskatoon, conducted an analysis of two double-blind risperidone studies of children aged 5-12 years with oppositional defiant disorder, conduct disorder, or disruptive behavior disorder-not otherwise specified. Of these children, 155 had comorbid ADHD.

Patients had received either risperidone and a stimulant (35), risperidone alone (43), placebo and a stimulant (38), or placebo alone (39). The mean daily dose of risperidone was 1.1 mg/kg.

Patients who received risperidone experienced a significant reduction in mean scores on the hyperactive subscale of the Nisonger Child Behavior Rating Form (NCBRF), compared with patients who received placebo.

The reduction in mean score was 7.2 in the risperidone and stimulant group, 7.3 in the risperidone alone group, 2.1 in the placebo and stimulant group, and 4.0 in the placebo alone group. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.